Given that accurately distinguishing the breast cancer subtype intra-operatively could provide immediate information to the surgeon and oncologist regarding further optimal chemotherapeutic options, we used the “always-on” HER2-645 probe, which can specifically target HER2, to detect the subtype of the breast cancer, as shown in Figure S5. The gene discussed is ERBB2; the disease is breast carcinoma.